MGMT启动子甲基化状态与IDH1及1p/19q对脑胶质瘤患者假性进展的诊断价值

脑胶质瘤是中枢神经系统中最常见的恶性肿瘤，起源于神经上皮细胞。术后联合放化疗已成为其标准治疗的组成部分，而MRI检查是随访颅内病变的常规手段。随访中出现的影像学变化，需进行真假进展的鉴别，由于二者的临床决策不同，因此真假进展的识别极为重要，但目前尚缺乏有效的鉴别手段。MGMT启动子、异柠檬酸脱氢酶-1（IDH1）及1p/19q分子标记物与假性进展相关，分子状态与影像学结合用于真假进展的鉴别，可能成为新的探索方向。本研究将对研究现状进行梳理，分析MGMT启动子、IDH1及1p/19q分子标记物在区分真假进展中的作用，为临床鉴别及精准医疗提供新参考。 

Diagnostic value of MGMT promoter methylation status,isocitrate dehydrogenase-1, and 1P/19Q for pseudoprogression in patients with glioma

Gliomas are the most common malignant tumors of the central nervous system. Postoperative combined chemoradiotherapy has become a standard part of the treatment, and MRI examination is a routine means to follow-up intracranial lesions. Imaging changes during follow-up should reflect the difference between true progression and pseudoprogression for appropriate clinical decision-making. However, this differentiation is still unclear. Recent studies have found that MGMT promoter, isocitrate dehydrogenase-1 (IDH1), and 1p/19q molecular markers are correlated with pseudoprogression. This combination of molecular biology and imaging for differentiation between true progression and pseudoprogression merits further exploration. This review based on the current research status and the role of MGMT promoter, IDH1, and 1p/19q molecular markers in differentiating between true progression and pseudoprogression, provides a new reference for clinical identification and precision medicine.